Back to Search
Start Over
Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes
- Source :
- Therapeutic Advances in Psychopharmacology, Vol 10 (2020)
- Publication Year :
- 2020
- Publisher :
- SAGE Publishing, 2020.
-
Abstract
- Background: Paliperidone palmitate 3-monthly (PP3M) is a second-generation, long-acting injectable antipsychotic formulation indicated for the maintenance treatment of adults with schizophrenia first stabilized with paliperidone palmitate 1-monthly (PP1M). This exploratory post hoc subgroup analysis of the 52-week, phase 3b REMISSIO study analysed outcomes according to patient age and disease duration in a naturalistic clinical setting. Methods: Outcomes of patients with schizophrenia were analysed according to age [3 years ( n = 233)]. The primary efficacy outcome was the proportion of patients achieving symptomatic remission according to the Andreasen criteria. Adverse events were monitored throughout the study. Results: At endpoint (last observation carried forward), 60.7% (95% CI: 51.4%, 69.4%) of younger patients and 54.1% of older patients (95% CI: 46.6%, 61.6%) achieved symptomatic remission. The proportions for patients with disease duration ⩽3 years and >3 years were similar: 57.8% (45.4%, 69.4%) versus 56.5% (49.8%, 62.9%). Functional remission was reached by 45.4% (36.2%, 54.8%) of patients aged
- Subjects :
- Therapeutics. Pharmacology
RM1-950
Psychiatry
RC435-571
Subjects
Details
- Language :
- English
- ISSN :
- 20451261 and 20451253
- Volume :
- 10
- Database :
- Directory of Open Access Journals
- Journal :
- Therapeutic Advances in Psychopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.b3fa4be270c14f9fa42165c0eeb276ea
- Document Type :
- article
- Full Text :
- https://doi.org/10.1177/2045125320981500